In vitro activity of combinations of beta-lactam antibiotics with beta-lactamase inhibitors against cephalosporinase-producing bacteria
- PMID: 2556277
- DOI: 10.1007/BF02185845
In vitro activity of combinations of beta-lactam antibiotics with beta-lactamase inhibitors against cephalosporinase-producing bacteria
Abstract
Combinations of different beta-lactam antibiotics, including cefotaxime, with three beta-lactamase inhibitors were tested against cephalosporinase producing bacterial strains. The most significant antagonism was obtained with a combination of clavulanic acid and cefotaxime, while almost no antagonism was observed with sulbactam and tazobactam. In strains belonging to five different species there was a correlation between the levels of cephalosporinase produced after exposure to different concentrations of inhibitors and the MICs of cefotaxime combined with the same concentrations of inhibitors. It is concluded that there is little likelihood of antagonism between beta-lactam antibiotics and sulbactam or tazobactam.
Similar articles
-
Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations.Antimicrob Agents Chemother. 1990 Apr;34(4):622-7. doi: 10.1128/AAC.34.4.622. Antimicrob Agents Chemother. 1990. PMID: 2344169 Free PMC article.
-
Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.Braz J Infect Dis. 2000 Feb;4(1):22-8. Braz J Infect Dis. 2000. PMID: 10788842
-
Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).Diagn Microbiol Infect Dis. 1989 Nov-Dec;12(6):481-8. doi: 10.1016/0732-8893(89)90082-5. Diagn Microbiol Infect Dis. 1989. PMID: 2560420
-
Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.Pharmacotherapy. 2000 Sep;20(9 Pt 2):213S-218S; discussion 224S-228S. doi: 10.1592/phco.20.14.213s.35045. Pharmacotherapy. 2000. PMID: 11001328 Review.
-
Evolution of beta-lactamase inhibitors.Rev Infect Dis. 1991 Jul-Aug;13 Suppl 9:S727-32. doi: 10.1093/clinids/13.supplement_9.s727. Rev Infect Dis. 1991. PMID: 1656513 Review.
Cited by
-
Antimicrobial prescriptions and adherence to prudent use guidelines for selected canine diseases in Switzerland in 2016.Vet Rec Open. 2020 Mar 9;7(1):e000370. doi: 10.1136/vetreco-2019-000370. eCollection 2020. Vet Rec Open. 2020. PMID: 32201578 Free PMC article.
-
Three decades of beta-lactamase inhibitors.Clin Microbiol Rev. 2010 Jan;23(1):160-201. doi: 10.1128/CMR.00037-09. Clin Microbiol Rev. 2010. PMID: 20065329 Free PMC article. Review.
-
Cefotaxime. An update of its pharmacology and therapeutic use.Drugs. 1990 Oct;40(4):608-51. doi: 10.2165/00003495-199040040-00008. Drugs. 1990. PMID: 2083516 Review.
-
Antimicrobial use for selected diseases in cats in Switzerland.BMC Vet Res. 2019 Mar 14;15(1):94. doi: 10.1186/s12917-019-1821-0. BMC Vet Res. 2019. PMID: 30871537 Free PMC article.
-
Evaluation of the automated phoenix system for potential routine use in the clinical microbiology laboratory.J Clin Microbiol. 2004 Apr;42(4):1542-6. doi: 10.1128/JCM.42.4.1542-1546.2004. J Clin Microbiol. 2004. PMID: 15071001 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical